Data presented at the European Society of Cardiology meeting give a boost to leadless pacemaking technology, which a Cleveland Clinic co-investigator calls “a big leap forward.”
Current Cleveland Clinic heart and vascular studies include two on leadless pacemakers, one on evolocumab for statin intolerance and one on gut flora reduction after dietary intervention.
Five new technologies—subcutaneous ICDs, contact force ablation catheters,
leadless pacemakers, a vagal nerve stimulator and a left atrial appendage occlusion device—are making EP procedures safer and more effective.
At one-tenth the size of their traditional counterparts, leadless pacemakers hold the promise of fewer infections, dislodgements and failures. U.S. studies are underway to put that promise to the test.